Implications of an SSRI Generic Step Therapy Pharmacy Benefit Design: An Economic Model in Anxiety DisordersByPatt Ellen Panzer, MD, MPH,Timothy S. Regan, BPharm, RPh, CPh,Evelyn Chiao, PharmD,Matthew W. Sarnes, PharmDOctober 20th 2005
Adherence to Paroxetine CR Compared With Paroxetine IR in a Medicare-eligible Population With Anxiety DisordersByMatthew S. Keene, MD,Michael T. Eaddy, PharmD, PhD,Winnie W. Nelson, PharmD, MS,Matthew W. Sarnes, PharmDOctober 20th 2005
Differences in Total Medical Costs Across the SSRIs for the Treatment of Depression and AnxietyByDavid V. Sheehan, MD, MBA,Michael T. Eaddy, PharmD, PhD,Manan B. Shah, PharmD, PhD,Robert P. Mauch, Jr, PharmD, PhDOctober 20th 2005
Anxiety Disorders in the 21st Century: Status, Challenges, Opportunities, and Comorbidity With DepressionByC. Lindsay DeVane, PharmD,Evelyn Chiao, PharmD,Meg Franklin, PharmD,Eric J. Kruep, PharmD, MSOctober 20th 2005
